Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Sales and Divestitures: 2016-2024

Historic Gains from Sales and Divestitures for Theravance Biopharma (TBPH) over the last 9 years, with Dec 2024 value amounting to $1.6 million.

  • Theravance Biopharma's Gains from Sales and Divestitures rose 13.27% to $336,744 in Q3 2025 from the same period last year, while for Sep 2025 it was $336,744, marking a year-over-year increase of 13.27%. This contributed to the annual value of $1.6 million for FY2024, which is 0.64% down from last year.
  • Theravance Biopharma's Gains from Sales and Divestitures amounted to $1.6 million in FY2024, which was down 0.64% from $1.7 million recorded in FY2023.
  • Theravance Biopharma's 5-year Gains from Sales and Divestitures high stood at $3.8 million for FY2022, and its period low was $1.6 million during FY2024.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.7 million (2023), whereas its average is $2.4 million.
  • As far as peak fluctuations go, Theravance Biopharma's Gains from Sales and Divestitures surged by 45.84% in 2020, and later tumbled by 56.17% in 2023.
  • Theravance Biopharma's Gains from Sales and Divestitures (Yearly) stood at $1.9 million in 2020, then skyrocketed by 40.63% to $2.7 million in 2021, then skyrocketed by 40.44% to $3.8 million in 2022, then slumped by 56.17% to $1.7 million in 2023, then fell by 0.64% to $1.6 million in 2024.